The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review

Jacqueline K Kueper, Mark Speechley, Manuel Montero-Odasso, Jacqueline K Kueper, Mark Speechley, Manuel Montero-Odasso

Abstract

The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) was developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease. Advancements in the research field have shifted focus toward pre-dementia populations, and use of the ADAS-Cog has extended into these pre-dementia studies despite concerns about its ability to detect important changes at these milder stages of disease progression. If the ADAS-Cog cannot detect important changes, our understanding of pre-dementia disease progression may be compromised and trials may incorrectly conclude that a novel treatment approach is not beneficial. The purpose of this review was to assess the performance of the ADAS-Cog in pre-dementia populations, and to review all modifications that have been made to the ADAS-Cog to improve its measurement performance in dementia or pre-dementia populations. The contents of this review are based on bibliographic searches of electronic databases to locate all studies using the ADAS-Cog in pre-dementia samples or subsamples, and to locate all modified versions. Citations from relevant articles were also consulted. Overall, our results suggest the original ADAS-Cog is not an optimal outcome measure for pre-dementia studies; however, given the prominence of the ADAS-Cog, care must be taken when considering the use of alternative outcome measures. Thirty-one modified versions of the ADAS-Cog were found. Modification approaches that appear most beneficial include altering scoring methodology or adding tests of memory, executive function, and/or daily functioning. Although modifications improve the performance of the ADAS-Cog, this is at the cost of introducing heterogeneity that may limit between-study comparison.

Keywords: ADAS-Cog; literature review; mild cognitive impairment; outcome measures.

Figures

Fig.1
Fig.1
Timeline of ADAS-Cog 11 modifications.

References

    1. Llano DA, Laforet G, Devanarayan V (2011) Derivation of a new ADAS-cog composite using tree-based multivariate analysis: Prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 25, 73–84.
    1. Podhorna J, Krahnke T, Shear M, E Harrison J (2016) Alzheimer’s Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: Change over time and the effect of enrichment strategies. Alzheimers Res Ther 8, 8.
    1. Graham DP, Cully JA, Snow AL, Massman P, Doody R (2004) The Alzheimer’s disease assessment scale-cognitive subscale: Normative data for older adult controls. Alzheimer Dis Assoc Disord 18, 236–240.
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int psychogeriatrics 9, 65–69.
    1. Cooper C, Sommerlad A, Lyketsos CG, Livingston G (2015) Modifiable predictors of dementia in Mild Cognitive Impairment: A systematic review and meta-analysis. Am J Psychiatry 172, 323–334.
    1. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L (2014) Mild cognitive impairment: A concept in evolution. J Intern Med 275, 214–228.
    1. Ueckert S, Plan EL, Ito K, Karlsson MO, Corrigan B, Hooker AC (2014) Improved utilization of ADAS-Cog assessment data through Item Response Theory based Pharmacometric Modeling. Pharm Res 31, 2152–2165.
    1. Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: A systematic review. J Alzheimers Dis 12, 23–35.
    1. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ (2004) Mild Cognitive Impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61, 59–66.
    1. Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JPG, Mayeux R (2008) Frequency and course of Mild Cognitive Impairment in a multiethnic community. Ann Neurol 63, 494–506.
    1. Apostolova LG, Cummings JL (2008) Neuropsychiatric manifestations in Mild Cognitive Impairment: A systematic review of the literature. Dement Geriatr Cogn Disord 25, 115–126.
    1. Plassman BL, Williams JW, Burke JR, Holsinger T, Benjamin S (2010) Factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 153, 182–193.
    1. Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE (2013) Efficacy and safety of cognitive enhancers for patients with Mild Cognitive Impairment: A systematic review and meta-analysis. CMAJ 185, 1393–1401.
    1. Reijnders J, van Heugten C, van Boxtel M (2013) Cognitive interventions in healthy older adults and people with mild cognitive impairment: A systematic review. Ageing Res Rev 12, 263–275.
    1. Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A (2013) The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement 9, 1–19.
    1. Aisen PS (2015) Cognitive/clinical endpoints for pre-dementia AD trials. J Prev Alzheimers Dis 2, 82–84.
    1. Rosen WG, Mohs RC, Davis KL (1984) A new rating Scale for Alzheimer’s disease. Am J Psychiatry 141, 1356–1364.
    1. Pyo G, Elble RJ, Ala T, Markwell SJ (2006) The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer Disease Assessment Scale-Cognitive Subscale. Alzheimer Dis Assoc Disord 20, 16–22.
    1. Zanotta D, Puricelli S, Bonoldi G (2014) Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: A noncomparative, exploratory clinical study. Neuropsychiatr Dis Treat 10, 225–230.
    1. Wouters H, Appels B, van der Flier WM, van Campen J, Klein M, Zwinderman AH, Schmand B, van Gool WA, Scheltens P, Lindeboom R (2012) Improving the accuracy and precision of cognitive testing in mild dementia. J Int Neuropsychol Soc 18, 314–322.
    1. Alexander GE, Satalich TA, Shankle WR, Batchelder WH (2016) A cognitive psychometric model for the psychodiagnostic assessment of memory-related deficits. Psychol Assess 28, 279–293.
    1. Zec RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R (1992) Alzheimer Disease Assessment Scale: Useful for both early detection and staging of dementia of the Alzheimer types. Alzheimer Dis Assoc Disord 6, 89–102.
    1. Connor DJ, Sabbagh MN (2008) Administration and scoring variance on the ADAS-Cog. J Alzheimers Dis 15, 461–464.
    1. Herholz K, Westwood S, Haense C, Dunn G (2011) Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 52, 1218–1226.
    1. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE (2012) The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): An expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav 6, 489–501.
    1. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Sjaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010) Alzheimer’s Disease Neuroimaging Initiative (ADNI) Clinical characterization. Neurology 74, 201–209.
    1. Mahoney R, Johnston K, Katona C, Maxmin K, Livingston G (2005) The TE4D-Cog: A new test for detecting early dementia in English-speaking populations. Int J Geriatr Psychiatry 20, 1172–1179.
    1. Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS (2011) Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of Mild Cognitive Impairment but not Alzheimer Disease. Alzheimer Dis Assoc Disord 25, 122–127.
    1. Zhang N, Song X, Zhang Y, Chen W, D’Arcy RC, Darvesh S, Fisk JD, Rockwood K (2011) An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer’s disease, mild cognitive impairment, and normal aging: A follow-up study. J Alzheimers Dis 26, 359–367.
    1. Bouallègue F Ben, Mariano-Goulart D, Payoux P (2017) Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther 9, 32.
    1. Torosyan N, Mason K, Dahlbom M, Silverman DHS (2017) Value ofFDG-PET scans of non-demented patients in predicting rates offuture cognitive and functional decline. Eur J Nucl Med MolImaging 44, 1355–1363.
    1. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC (2004) Impact of APOE in mild cognitive impairment. Neurology 63, 1898–1901.
    1. Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC, Alzheimer’s Disease Neuroimaging Initiative (2010) Volume changes in Alzheimer’sdisease and mild cognitive impairment: Cognitive associations. Eur Radiol 20, 674–682.
    1. Steenland K, Zhao L, Goldstein F, Cellar J, Lah J (2014) Biomarkers for predicting cognitive decline in those with normal cognition. J Alzheimers Dis 40, 587–594.
    1. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D (2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6, 502–516.
    1. Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR (2015) Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement 11, 226–235.
    1. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72, 578–586.
    1. Cronk BB, Johnson DK, Burns JM (2010) Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 24, 126–130.
    1. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Petersen RC, Ascherio A, Aisen PS (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6, 23–28.
    1. Kennedy RE, Schneider LS, Cutter GR (2012) Biomarker positive and negative subjects in the ADNI cohort: Clinical characterization. Curr Alzheimer Res 9, 1135–1141.
    1. Kennedy RE, Cutter GR, Schneider LS (2014) Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and MCI due to AD. Alzheimers Dement 10, 349–359.
    1. Kennedy RE, Cutter GR, Wang G, Schneider LS (2016) Post hoc analyses of ApoE genotype-defined subgroups in clinical trials. J Alzheimers Dis 50, 1205–1215.
    1. Mackin RS, Insel P, Tosun D, Mueller SG, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Lee JY, Jack CR Jr, Aisen PS, Petersen RC, Weiner MW (2013) The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry 21, 906–914.
    1. McGough EL, Cochrane BB, Pike KC, Logsdon RG, McCurry SM, Teri L (2013) Dimensions of physical frailty and cognitive function in older adults with amnestic mild cognitive impairment. Ann Phys Rehabil Med 56, 329–341.
    1. Portelius E, Zetterberg H, Skillbäck T, Tornqvist U, Andreasson U, Trojanowski JQ, weiner MW, Shaw LM, Mattsson N, Blennow K (2015) Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer’s disease. Brain 138, 3373–3385.
    1. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Rio ID, Trabucchi M, Padovani A (2006) Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic Mild Cognitive Impairment. Int J Geriatr Psychiatry 21, 550–555.
    1. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Trabucchi M, Padvani A (2008) Mild parkinsonian signs and psycho-behavioral symptoms in subjects with mild cognitive impairment. Int Psychogeriatr 20, 86–95.
    1. Schneider LS, Insel PS, Weiner MW (2011) Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch Neurol 68, 58–66.
    1. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J (2014) Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimers Res Ther 6, 36.
    1. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS (2010) Influence of Apolipoprotein E e4 on rates ofcognitive and functional decline in Mild Cognitive Impairment. Alzheimers Dement 6, 412–419.
    1. Bettermann K, Arnold A, Williamson J, Rapp S, Sink K, Toole JF, Carlson MC, Yasar S, DeKosky S, Burke GL (2012) Statins, risk of dementia and cognitive function: Secondary analysis of the Ginko Evaluation of Memory Study (GEMS). J Stroke Cerebrovasc Dis 21, 436–444.
    1. Perneczky R, Pohl C, Sorg C, Hartmann J, Komossa K, Alexopoulos P, Wagenpfeil S, Kurz A (2006) Complex activities of daily living in mild cognitive impairment: Conceptual and diagnostic issues. Age Ageing 35, 240–245.
    1. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbage MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ (2012) Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 79, 1636–1644.
    1. Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbage MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ (2014) Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry 19, 1044–1051.
    1. Gonzales MM, Insel PS, Nelson C, Tosun D, Mattsson N, Mueller SG, Sacuiu S, Bickford D, Weiner MW, Mackin RS (2017) Cortical atrophy is associated with accelerated cognitive decline in mild cognitive impairment with subsyndromal depression. Am J Geriatr Psychiatry 25, 980–991.
    1. Landau S, Horng A, Fero A, Jagust W (2016) Amyloid negativity in clinically diagnosed ADNI Alzheimer’s disease and MCI patients. Neurology 86, 1377–1385.
    1. Moon B, Kim S, Park YH, Lim JS, Youn YC, Kim SY, Jang JW (2017) Depressive symptoms are associated with progression to dementia in patients with amyloid-positive mild cognitive impairment. J Alzheimers Dis 58, 1255–1264.
    1. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neirol 68, 1257–1266.
    1. Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH (2016) Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer’s disease biomarker related cognitive decline? . Eur J Neurol 23, 948–957.
    1. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI (2012) Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis 1, 280–291.
    1. Furio AM, Brusco LI, Cardinali DP (2007) Possible therapeutic value of melatonin in Mild Cognitive Impairment: A retrospective study. J Pineal Res 43, 404–409.
    1. De Beaumont L, Pelleieux S, Lamarre-Theroux L, Dea D, Poirier J (2016) Butyrylcholinesterase K and Apolipoprotein E-e4 reduce the age of onset of Alzheimer’s disease, accelerate cognitive decline, and modulate donepezil response in mild cognitively impaired subjects. J Alzheimers Dis 54, 913–922.
    1. Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, Moller HJ, Hampel H, Buerger K (2011) Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer’s disease: A pilot study. J Alzheimers Dis 25, 679–694.
    1. Buschert VC, Giegling I, Teipel SJ, Jolk S, Hampel H, Rujescu D, Buerger K (2012) Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. J Clin Psychiatry 73, e1492–e1498.
    1. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Prog Neuropsychopharmacol Biol Psychiatry 32, 1538–1544.
    1. Dubois B, Zaim M, Touchon J, Vellas B, Robert P, Murphy MF, Pujadas-Navines F, Rainer M, Soininen H, Riordan HJ, Kanony-Truc C (2012) Effect of six months of treatment with V0191 in patientswith suspected prodromal Alzheimer’s disease. J AlzheimersDis 29, 527–535.
    1. Förster S, Buschert VC, Teipel SJ, Friese U, Buchholz HG, Drzezga A, Hampel H, Bartenstein P, Buerger K (2011) Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer’s disease. J Alzheimer 26, 337–348.
    1. Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A (2017) IVIG treatment of mild cognitive impairment dueto Alzheimer’s disease: A randomised double-blinded exploratorystudy of the effect on brain atrophy, cognition and conversion todementia. J Neurol Neurosurg Psychiatry 88, 106–112.
    1. Lin C-H, Chen P-K, Chang Y-C, Chuo L-J, Chen Y-S, Tsai GE, Lane H-Y (2014) Benzoate, a d-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial. Biol Psychiatry 75, 678–685.
    1. Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, Ichise M, Manly J, Devanand DP, Bagiella E (2016) Metformin in amnestic mild cognitive impairment: Results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis 51, 501–514.
    1. Miao Y-C, Tian J-Z, Shi J, Mao M (2012) Effects of chinese medicine for toninfying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: A randomized double-blind and parallel-controlled trial. J Chinese Integr Med 10, 390–397.
    1. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donpezil for the treatment of mild cognitive impairment. NEJM 352, 2379–2388.
    1. De Gobbi Porto FH, Coutinho AMN, De Sa Pinto AL, Gualano B, de Souza Duran FL, Prando S, Ono CR, Spindola L, de Oliveira MO, do Vale PHF, Nitrini R, Buchpiguel CA, Brucki SMD (2015) Effects of aerobic training on cognition and brain glucose metabolism in subjects with Mild Cognitive Impairment. J Alzheimers Dis 46, 747–760.
    1. Reuter I, Mehnert S, Sammer G, Oechsner M, Engelhardt M (2012) Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinsons disease.. J Aging Res 2012, 1–15.
    1. Singh MAF, Gates N, Saigal N, Wilson GC, Meiklejohn J, Brodaty H, Wen W, Singh N, Baune BT, Suo C, Baker MK, Foroughi N, Wang Y, Sachdev PS, Valenzuela M (2014) The Study of Mental and Resistance Training (SMART) Study-resistance training and/or cognitive training in mild cognitive impairment: A randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc 15, 873–880.
    1. Snitz BE, Meara ESO, Carlson MC, Arnold AM, Ives DG (2009) Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA 302, 2663–2670.
    1. Suzuki T, Shimada H, Makizako H, Doi T, Yoshida D, Ito K, Shimokata H, Washimi Y, Endo H, Kato T (2013) A randomized controlled trial of multicomponent exercise in older adults with Mild Cognitive Impairment. PLoS One 8, e1483–e1483.
    1. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA (2005) A randomized, double-blind, study of rofecoxib in patients with Mild Cognitive Impairment. Neuropsychopharmacology 30, 1204–1215.
    1. Bruno M, Sicari R, Stea F, Ghiadoni L, Ungar A, Bonuccelli U, Tognoni G, Gargani L, D’Angelo G, Pratali L, Berardi N, Maffei L, Picano E (2017) Effect of a multimodality training on cognitive and vascular function in MCI patients with or without hypertension: The train the brain - mind the vessel study. Cerebrovascular Disease, Stroke and Cognitive Dysfunction Abstracts, e5.
    1. Gu C, Shen T, An H, Yuan C, Zhang T, Gu T (2017) Clinical therapy of Di-Huang-Yi-Zhi in treating patients with amnestic mild cognitive impairment: A prospective, open-label and randomized study. Int J Clin Exp Med 10, 3554–3560.
    1. Pakdaman H, Amini Harandi A, Abbasi M, Kasmaei HD, Ashrafi F, Gharagozli K, Assarzadegan F, Behnam B, Arabahmadi M (2017) Efficacy and safety of MLC601 in the treatment of Mild Cognitive Impairment: A pilot, randomized, double-blind, placebo-controlled study. Dement Geriatr Cogn Disord Extra 7, 136–142.
    1. Caroli A, Prestia A, Wade S, Chen K, Ayutyanont N, Landau SM, Madison CM, Haense C, Herholz K, Reiman EM, Jagust WJ, Frisoni GB (2015) Alzheimer’s disease biomarkers as outcome measures for clinical trials in MCI. Alzheimer Dis Assoc Disor 29, 101–109.
    1. Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D (2013) Estimatingsample sizes for pre-dementia Alzheimer’s trials based on the Alzheimer’s Disease Neuroimaging Initiative. NeurobiolAging 34, 62–72.
    1. Ho AJ, Hua X, Lee S, Leow AD, Yanovsky I, Gutman B, Dinov ID, Lepore N, Stein JL, Toga AW, Jack CR CR, Bernstein MA, Reiman, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2010) Comparing 3 T and 1.5 T MRI for tracking Alzheimer’s Disease progression with tensor-based morphometry. Hum Brain Mapp 31, 499–514.
    1. Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, Gutman B, Toga AW, Jack CR Jr, Berstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM, Alzheimer’s Disease Neuroimaging Initiative (2009) Optimizing power to trackbrain degeneration in Alzheimer’s disease and Mild Cognitive Impairment with tensor-based morphometry: An ADNI study of 515 subjects. Neuroimage 48, 668–681.
    1. Wouters H, Gool WAVW van, Schmand B, Lindeboom R (2008) Revising the ADAS-cog for a more accurate assessment of cognitive impairment. J Alzheimers Dis 22, 236–244.
    1. Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F (2012) Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer’s disease. Int J Geriatr Psychiatry 27, 15–21.
    1. Balsis S, Unger AA, Benge JF, Geraci L, Doody RS (2012) Gainingprecision on the Alzheimer’s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores. Alzheimers Dement 8, 288–294 .
    1. Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK (2015) New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers Res Ther 7, 1–17.
    1. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 11, S13–S21.
    1. Ferris SH (1999) Cognitive outcome measures. Alzheimer Dis Assoc Disord 13, S140–S142.
    1. Ferris SH (2003) General measures of cognition. Int Psychogeriatr 15, 215–217.
    1. Lowe DA, Balsis S, Benge JF, Doody RS (2015) Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer’s disease: Implications for predicting instrumental activities of daily living. Psychol Assess 27, 1234–1240.
    1. O’Halloran J, Kemp A, Salmon D, Tariot P, Schneider L (2011) Psychometric comparison of standard and computerized administration of the Alzheimer’s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog). Curr Alzheimer Res 8, 323–328.
    1. Carusone SC, Goldsmith CH, Smieja M, Loeb M (2006) Summarymeasures were a useful alternative for analyzing therapeuticclinical trial data. J Clin Epidemiol 59, 387–392.
    1. Inoue M, Jimbo D, Taniguchi M, Urakami K (2011) Touch Panel-type Dementia Assessment Scale: A new computer-based rating scale for Alzheimer’s disease. Psychogeriatrics 11, 28–33.
    1. Wouters H, Van Campen J, Appels B, Lindeboom R, Buiter M, de Haan RJ, Zwinderman AH, van Gool WA, Schmand B (2011) Does adaptive cognitive testing combine efficiency with precision? prospective findings. J Alzheimers Dis 25, 595–603.
    1. Wessels A, Siemers E, Andersen S, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS (2015) A combined measure of cognition and function for clinical trials: The integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alzheimers Dis 2, 227–241.
    1. Huang Y, Ito K, Billing CB, Anziano RJ (2015) Development of a straightforward and sensitive scale for MCI and early AD clinical trials. Alzheimers Dement 11, 404–414.
    1. Grochowalski JH, Liu Y, Siedlecki KL (2016) Examining the reliability of ADAS-Cog change scores. Aging, Neuropsychol Cogn 23, 513–529.
    1. Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A (2016) ADCOMS: A composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry 87, 993–999.
    1. Montero-Odasso MM, Sarquis-Adamson Y, Speechley M, Borrie MJ, Hachinski VC, Wells J, Riccio PM, Schpira M, Sejdic E, Camicioli RM, Bartha R, McIlroy WE, Muir-Hunter S (2017) Association of dual-task gait with incident dementia in mild cognitive impairment. JAMA Neurol 54, S154.
    1. Kueper JK, Speechley M, Lingum NR, Montero-Odasso M (2017) Motorfunction and incident dementia: A systematic review andmeta-analysis. Age Ageing 46, 729–738.
    1. Loewenstein DA, Curiel RE, Greig MT, Bauer RM, Rosado M, Bowers D, Wicklund M, Crocco E, Pontecorvo M, Joshi AD, Rodriguez R, Barker WW, Hidalgo J, Duara R (2016) A novel cognitive stress test for the detection of preclinical Alzheimer disease: Discriminative properties and relation to amyloid load. Am J Geriatr Psychiatry 24, 804–813.
    1. Crocco EA, Loewenstein DA, Curiel RE, Alperin N, Czaja SJ, Harvey PD, Sun X, Lenchus J, Raffo A, Penate A, Melo J, Sang L, Valdivia R, Cardenas K (2018) A novel cognitive assessment paradigm to detect pre-mild cognitive impairment (PreMCI) and the relationship to biological markers of Alzheimer’s disease. J Psychiatr Res 96, 33–38.
    1. Matias-Guiu JA, Cabrera-Martín MN, Curiel RE, Valles-Salgado M, Rognoni T, Moreno-Ramos T, Carreras JL, Loewenstein DA, Matias-Guiu J (2017) Comparison between FCSRT and LASSI-L to detect early stage Alzheimer’s disease. J Alzheimers Dis 61, 103–111.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅